Simcere Pharmaceutical Group Limited
2096
株式のランク
#4480
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the... Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
株価
$1.32
時価総額
$3.40B
変化（1日）
-4.51%
変化（1年）
-19.88%
国
CN
取引 Simcere Pharmaceutical Group Limited (2096)
カテゴリー
Healthcare
Simcere Pharmaceutical Group Limited（2096）のP/B比率
October 2026 時点のP/B比率 TTM: 2.39
Simcere Pharmaceutical Group Limited の最新の財務報告および株価によると、現在のP/B比率（TTM）は 2.39 です。2024 年末時点でのP/B比率は 2.39 でした。
Simcere Pharmaceutical Group Limited の P/B 比率の履歴（2012 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 2.39 | -15.80% |
| 2025 | 2.84 | 19.18% |
| 2024 | 2.39 | 9.48% |
| 2023 | 2.18 | -42.05% |
| 2022 | 3.76 | 26.70% |
| 2021 | 2.97 | -19.91% |
| 2020 | 3.70 | -78.54% |
| 2019 | 17.26 | 7.61% |
| 2018 | 16.04 | 19.86% |
| 2017 | 13.38 | 2,739.85% |
| 2012 | 0.47 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 6.6964 | 180.02% |
US
|
|
| 13.6307 | 469.99% |
US
|
|
| 4.4521 | 86.17% |
AU
|
|
| 4.2241 | 76.64% |
BE
|
|
| 6.3632 | 166.09% |
NL
|
